Read by QxMD icon Read

HBsAg seroconversion

Seyma Katrinli, G Nilay Karatas Erkut, Kamil Ozdil, Feruze Yilmaz Enc, Oguzhan Ozturk, Resul Kahraman, Ilyas Tuncer, Gizem Dinler Doganay, Levent Doganay
AIM: Chronic hepatitis B (CHB) is a global health problem. Recent genome-wide association studies (GWAS) exposed signifi-cant association between the human leukocyte antigen (HLA) class II region, including both DP and DQ loci, and chronic hepatitis B. Previous research also indicated the involvement of adaptive immune system in Hepatitis B seroconversion. The aim of this study is to investigate possible polymorphisms in the HLA-DP locus that can contribute to immune response to Hepatitis B virus (HBV)...
July 2017: Acta Gastro-enterologica Belgica
Bo Wang, Ivana Carey, Matthew Bruce, Sarah Montague, Geoff Dusheiko, Kosh Agarwal
HBeAg seroconversion marks an important spontaneous change and treatment end-point for HBeAg-positive patients and is a pre-requisite for HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg-positive patients treated with nucleos(t)ide analogues (NA). Data and samples from 118 HBeAg-positive adults (genotypes A-G) started on NA between Jan 2005-Sept 2016 were retrospectively analysed at several time-points...
March 13, 2018: Journal of Viral Hepatitis
S Katrinli, G N K Erkut, K Ozdil, F Y Enc, R Kahraman, I Tuncer, G D Doganay, L Doganay
AIM: Chronic hepatitis B (CHB) is a global health problem. Recent genome-wide association studies (GWAS) exposed signifi-cant association between the human leukocyte antigen (HLA) class II region, including both DP and DQ loci, and chronic hepatitis B. Previous research also indicated the involvement of adaptive immune system in Hepatitis B seroconversion. The aim of this study is to investigate possible polymorphisms in the HLA-DP locus that can contribute to immune response to Hepatitis B virus (HBV)...
July 2017: Acta Gastro-enterologica Belgica
S Van Hees, S Bourgeois, H Van Vlierberghe, T Sersté, S Francque, P Michielsen, D Sprengers, H Reynaert, J Henrion, S Negrin Dastis, J Delwaide, L Lasser, J Decaestecker, H Orlent, F Janssens, G Robaeys, I Colle, P Stärkel, C Moreno, F Nevens, T Vanwolleghem
BACKGROUND: Stopping nucleos(t)ide analogues (NA) after hepatitis B e antigen (HBeAg) seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian cohorts are scarce. Clinical course, outcomes and immunological aspects of chronic hepatitis B infections differ substantially between distinct ethnicities. AIM: The aim of this study was to determine relapse rates, factors predicting relapse and clinical outcomes after nucleos(t)ide analogue cessation in a large, predominantly Caucasian cohort of chronic hepatitis B patients with nucleos(t)ide analogue-induced HBeAg seroconversion...
March 2, 2018: Alimentary Pharmacology & Therapeutics
Piero Colombatto, Cristiana Barbera, Flavia Bortolotti, Anna M Maina, Francesco Moriconi, Daniela Cavallone, Pierluigi Calvo, Filippo Oliveri, Ferruccio Bonino, Maurizia R Brunetto
BACKGROUND: Selection of HBeAg defective HBV mutants (mt) during childhood might influence infection outcome in adults. Aim of this study was to correlate the dynamics of Pre-Core HBV mutant (Pre-C mt) selection with virological/clinical outcomes in children followed-up until adulthood. METHODS: Eighty subjects (50-M/30-F), 70 HBeAg-positive (87.5%) and 10 (12.5%) HBeAg-negative/anti-HBe-positive at the admission, mostly genotype D infected (91.2%), with median age of 6...
February 28, 2018: Journal of Medical Virology
Meng-Lan Wang, Juan Liao, Bing Wei, Dong-Mei Zhang, Ming He, Ming-Chuan Tao, En-Qiang Chen, Hong Tang
AIM: Recent studies revealed that both quantitative hepatitis B surface antigen (qHBsAg) and hepatitis B core-related antigen (qHBcrAg) could serve as a good marker for predicting treatment response and indirectly reflecting intrahepatic cccDNA levels. This study aimed to compare the value of qHBsAg and qHBcrAg in predicting HBeAg seroconversion among patients undergoing PEG-IFN therapy. METHODS: A total of 31 HBeAg-positive patients, who underwent PEG-IFN therapy for 12 months and follow-up for six months were retrospectively included in this study...
February 20, 2018: Infectious Diseases
Tien-Ching Lin, Yen-Cheng Chiu, Hung-Chih Chiu, Wen-Chun Liu, Pin-Nan Cheng, Chiung-Yu Chen, Ting-Tsung Chang, I-Chin Wu
AIM: To investigate the utility of hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B patients during long-term entecavir treatment. METHODS: This retrospective study included treatment-naïve chronic hepatitis B patients who received at least 2 years of consecutive entecavir treatment. Patients were followed up at three to six month intervals with liver biochemistry, hepatitis B virus DNA, and abdominal sonography. In hepatitis B e antigen (HBeAg)-positive patients, HBeAg levels were assessed every three to six month until results became negative...
February 14, 2018: World Journal of Gastroenterology: WJG
Chao-Wei Hsu, Wei-Wen Su, Chuan-Mo Lee, Cheng-Yuan Peng, Wan-Long Chuang, Jia-Horng Kao, Heng-Cheng Chu, Yi-Hsiang Huang, Rong-Nan Chien, Yun-Fan Liaw
BACKGROUND: Efficacy of sequential therapy with nucleos(t)ide analogues and interferons versus monotherapy in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) remains unexplored. We aimed to assess efficacy and safety of sequential therapy with adefovir (ADV) or entecavir (ETV) followed by peginterferon (PEG-IFN) alfa-2a in Taiwanese patients with HBeAg-positive. METHODS: This randomized, placebo-controlled, double-blind trial was conducted at nine sites in Taiwan from April 2010 to October 2013...
February 15, 2018: Journal of the Formosan Medical Association, Taiwan Yi Zhi
Shishu Zhu, Hongfei Zhang, Yi Dong, Limin Wang, Zhiqiang Xu, Weiwei Liu, Yu Gan, Hongmei Tang, Dawei Chen, Fuchuan Wang, Pan Zhao
BACKGROUND & AIM: Chronic infection with hepatitis B virus (HBV) in children possesses a serious health problem worldwide. It remains unresolved how children with immune-tolerant chronic hepatitis B should be treated, who were commonly characterized by HBeAg positivity, high viral load, normal or mildly elevated ALT and no or minimal inflammation in liver histology. This trial aims to study the benefits of antiviral therapy in children with these characters. METHODS: This is a pilot open-lable randomized controlled study...
February 13, 2018: Journal of Hepatology
Tao Li, Feng Liu, Lixin Zhang, Qian Ye, Xiaoping Fan, Yan Xue, Lei Wang
Background/Aims: The optimal duration of nucleos(t)ide analogs (NAs) therapy in chronic hepatitis B (CHB) patients remains unsatisfactory. Previous studies have confirmed the important role of host genetic factors in determining the outcome of HBV infection. This study tries to determine the role of host genetic factors in predicting response status in CHB patients discontinuing NAs according to stringent cessation criteria. Patients and Methods: Participating patients came from a prospective NAs- discontinuation cohort since June 1999...
January 2018: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
Dong-Mei Zou, Dong-Dong Rong, Hong Zhao, Li Su, Wan-Ling Sun
RATIONALE: This report describes seroconversion of hepatitis B surface antigen (HBsAg) in a patient with marked iron overload caused by chronic hepatitis B (CHB) after receiving iron chelation therapy and discusses the role of iron chelation therapy in CHB. PATIENT CONCERNS: Increased serum ferritin level for 2 months. DIAGNOSIS: Secondary iron overload and CHB. INTERVENTION: To relieve iron load of the body, the patient underwent regular phlebotomy therapy and deferoxamine (DFO) therapy...
December 2017: Medicine (Baltimore)
Alessandro Collo, Paola Belci, Sharmila Fagoonee, Lucia Loreti, Valeria Gariglio, Ramona Parise, Paola Magistroni, Marilena Durazzo
BACKGROUND: Therapy in chronic hepatitis B (CHB) patients aims at improving their survival by preventing disease progression to cirrhosis and its complications. Entecavir (ETV) is currently a first line therapeutic agent recommended for the treatment of CHB. Our aim was to evaluate the long term outcome of a cohort of CHB patients treated with ETV. METHODS: Thirty-four patients treated with ETV for at least 6 months were included in this study. The virologic response was determined by the dosage of serum HBV-DNA, HBsAg, HBeAg, anti-HBs and anti-HBe antibodies...
January 10, 2018: Minerva Gastroenterologica e Dietologica
Berthold Bivigou-Mboumba, Marie Amougou-Atsama, Samira Zoa-Assoumou, Hervé M'boyis Kamdem, Guy Francis Nzengui-Nzengui, Angélique Ndojyi-Mbiguino, Richard Njouom, Sandrine François-Souquière
In Gabon, a central African country, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are endemic. In a recent study, conducted in a semi-urban area (Franceville, Gabon), HBV infection was found to be more prevalent among HIV infected individuals. This study aims to investigate the prevalence and genetic diversity of hepatitis B virus infection among HIV infected individuals, predominantly under antiretroviral therapy, living in fully urbanized area: Libreville, capital of Gabon. Serological and molecular tests were performed to detect HBV infection among patients living with HIV/AIDS (PLHA)...
2018: PloS One
Chien-Yuan Chen, Feng-Ming Tien, Aristine Cheng, Shang-Yi Huang, Wen-Chien Chou, Ming Yao, Jih-Luh Tang, Hwei-Fang Tien, Wang-Huei Sheng
BACKGROUND: The risk of Hepatitis B virus (HBV) reactivation in patients with different hematological malignancy except lymphoma were rarely known before. METHODS: A total of 1962 patients with hematological malignancy were enrolled and followed-up at the National Taiwan University Hospital between 2008 and 2013. The clinical characteristics, HBV serology, and laboratory data were retrospectively reviewed and analyzed. RESULTS: A total of 1962 patients comprising 1048 men and 914 women were studied...
January 8, 2018: BMC Gastroenterology
Xuerui Yi, Youcheng Yuan, Na Li, Lu Yi, Cuiling Wang, Ying Qi, Liang Gong, Guangze Liu, Xiangping Kong
BACKGROUND: Viral clearance of human HBV infection largely depends on the age of exposure. Thus, a mouse model with age-dependent immune response and immune-tolerance for HBV infection was established. METHODS: HBVRag1 mice were generated by crossing Rag1-/- mice with HBV-Tg mice. Following adoptive transfer of splenocytes adult (8-9 weeks old) and young (3 weeks old) HBVRag1 mice were named as HBVRag-ReA and HBVRag-ReY mice respectively. The biochemical parameters that were associated with viral load and immune function, as well as the histological evaluation of the liver tissues between the two mouse models were detected...
January 3, 2018: Vaccine
Do Young Kim, Ju Hyun Kim, Won Young Tak, Jong Eun Yeon, Joon Hyeok Lee, Jung Hwan Yoon, Youn Jae Lee, Byung Seok Lee, Byung Hoon Han, Han Chu Lee
Background and objective: Entecavir (ETV) is a standard of care for chronic hepatitis B (CHB). In a bioequivalence study, ETV from Dong-A ST (Baracle® ) was found to have a pharmacokinetic profile equivalent to ETV from Bristol-Myers Squibb (BMS) (Baraclude® ). The present study was conducted to evaluate the antiviral activity and safety of ETV from Dong-A ST in comparison to ETV from BMS in patients with CHB. Methods: In this multicenter, double-blind, active-controlled, stratified-randomized, parallel group, comparative trial, 118 treatment-naïve patients with CHB were randomly assigned to receive either 0...
2017: Drug Design, Development and Therapy
Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia
Although the efficacy of nucleos(t)ide analogue (NA) has been confirmed for treatment of chronic hepatitis B, long-term therapy has been recommended due to the high frequency of off-therapy viral DNA rebound and disease relapse. In this review, the RNA virion-like particles of hepatitis B virus (HBV) are integrated into the life cycle of HBV replication, and the potential significance of serum HBV RNA is systematically described. The production of HBV RNA virion-like particles should not be blocked by NA; in this regard, serum HBV RNA is found to be a suitable surrogate marker for the activity of intrahepatic covalently closed circular DNA (cccDNA), particularly among patients receiving NA therapy...
December 2017: Frontiers of Medicine
Xian Zhou, Shuang Geng, Shijie Zhang, Weidong Zhao, Gan Zhao, Yumei Wen, Xuanyi Wang, Bin Wang
Cytokine assays of host immune responses to vaccination can indicate vaccine efficacy. Here we tested the hypothesis that assays of the cytokine status of infected individuals prior to therapeutic vaccination might provide a guide to vaccine therapeutic efficacy. If so, cytokine analysis might be used to select appropriate patients for therapeutic vaccination. Data were obtained from a panel of 14 cytokine/chemokine assays that were done during a phase III clinical trial of HBsAg-HBIG therapeutic vaccine (YIC) treatment of chronic hepatitis B (CHB) patients...
November 17, 2017: Cytokine
X-J Ma, X-F Chen, W-L Chen, R Chen, J Huang, X-D Luo, J-Y Liao, X-P Chen
OBJECTIVE: To study the alteration of CD8+ memory T cell subsets under different immune statuses during the spontaneous clearance of hepatitis B virus (HBV) in Chinese patients with chronic HBV infection. PATIENTS AND METHODS: We analyzed Chinese patients with chronic HBV infection including 10 patients with Hepatitis B surface Antigen (HBsAg) spontaneous seroconversion, 25 patients with Hepatitis B virus e Antigen (HBeAg) spontaneous seroconversion, 25 patients with chronic hepatitis B (CHB), and 25 chronic HBV carriers...
October 2017: European Review for Medical and Pharmacological Sciences
X Yue, C Ge, S Zhuge, H He, H Yang, H Xu, A Huang, Y Zhao
Immunization with the hepatitis B vaccine is the most effective measure to prevent Hepatitis B Virus (HBV) infection. The aim of this study was to investigate the change in antibody levels induced by administration of the hepatitis B vaccine in children aged 1-16 year old in a large sample sized investigation. HBV markers were determined in 93 326 1- to 16-year-old hospitalized children who completed primary immunization as infants from south-west China, Chongqing. Analyses were performed on anti-HBs titre changes with increasing age, and the revaccination effect was evaluated in children aged 7-14...
November 1, 2017: Journal of Viral Hepatitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"